Phenethylisothiocyanate Alters Site- and Promoter-Specific Histone Tail Modifications in Cancer Cells

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Liu, Yi ^a   Chakravarty, Suvobrata ^a   Dey, Moul ^a  

^a SOUTH DAKOTA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 8; CD40 ANTIGEN; CYCLIN D1; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GELATINASE B; HISTONE H3; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; MATRILYSIN; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PHENETHYL ISOTHIOCYANATE; STAT1 PROTEIN;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CD40 ANTIGEN GENE; CHEMOKINE C-C MOTIF LIGAND 2 GENE; CHEMOPROPHYLAXIS; COLON CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEACETYLATION; DOSE TIME EFFECT RELATION; DOWN REGULATION; EPIGENETICS; GENE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HISTONE ACETYLATION; HISTONE METHYLATION; HISTONE MODIFICATION; HUMAN; HUMAN CELL; HUMAN GENOME; IN VITRO STUDY; INTERLEUKIN 8 GENE; INTRACELLULAR SIGNALING; MATRIX METALLOPROTEINASE 7 GENE; MATRIX METALLOPROTEINASE 9 GENE; NUCLEAR FACTOR OF KAPPA LIGHT CHAIN GENE ENHANCER IN B CELL 1 GENE; NUCLEOTIDE SEQUENCE; SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 GENE; UPREGULATION;

ACETYLATION; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMOKINES; COLONIC NEOPLASMS; DNA FRAGMENTATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONES; HUMANS; ISOTHIOCYANATES; MATRIX METALLOPROTEINASES; METHYLATION; PROMOTER REGIONS, GENETIC; PROTEIN PROCESSING, POST-TRANSLATIONAL; RNA, MESSENGER; TIME FACTORS; TRANSCRIPTION FACTORS;

EID: 84878384521     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064535     Document Type: Article

References (60)

1. Murphy SL, Xu J, Kochanek KD, (2012) Deaths: Preliminary Data for 2010. Natl Vital Stat Rep 60: 1-52.
2. Keum YS, Jeong WS, Kong AN, (2005) Chemopreventive functions of isothiocyanates. Drug News Perspect 18: 445-451.
3. Hopkins AL, (2008) Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol 4: 682-690.
4. Chen Y, Zhu J, Lum PY, Yang X, Pinto S, et al. (2008) Variations in DNA elucidate molecular networks that cause disease. Nature 452: 429-435.
5. Vidal M, Cusick ME, Barabasi AL, (2011) Interactome networks and human disease. Cell 144: 986-998.
6. Rodriguez-Paredes M, Esteller M, (2011) Cancer epigenetics reaches mainstream oncology. Nat Med 17: 330-339.
7. Kurdistani SK, (2011) Histone modifications in cancer biology and prognosis. Prog Drug Res 67: 91-106.
8. Du TT, Huang QH, (2007) [The roles of histone lysine methylation in epigenetic regulation]. Yi Chuan 29: 387-392.
9. Eberharter A, Becker PB, (2002) Histone acetylation: a switch between repressive and permissive chromatin. Second in review series on chromatin dynamics. EMBO Rep 3: 224-229.
10. Davis CD, Ross SA, (2007) Dietary components impact histone modifications and cancer risk. Nutr Rev 65: 88-94.
11. Huang J, Plass C, Gerhauser C, (2011) Cancer chemoprevention by targeting the epigenome. Curr Drug Targets 12: 1925-1956.
12. Dey M, Kuhn P, Ribnicky D, Premkumar V, Reuhl K, et al. (2010) Dietary phenethylisothiocyanate attenuates bowel inflammation in mice. BMC Chem Biol 10: 4.
13. Dey M, Ribnicky D, Kurmukov AG, Raskin I, (2006) In vitro and in vivo anti-inflammatory activity of a seed preparation containing phenethylisothiocyanate. J Pharmacol Exp Ther 317: 326-333.
14. Nishikawa A, Furukawa F, Lee IS, Tanaka T, Hirose M, (2004) Potent chemopreventive agents against pancreatic cancer. Curr Cancer Drug Targets 4: 373-384.
15. Ribnicky DM PA, Henry E, Raskin I, (2001) Seed of Barbarea verna as a rich source of phenethyl isothiocyanate to provide natural protection from environmental and dietary toxins. J Nutraceuticals Funct Med Foods 3: 22.
16. NCI-DCPC (1996) Clinical development plan: phenethyl isothiocyanate. J Cell Biochem Suppl 26: 149-157.
17. Del Prete A, Allavena P, Santoro G, Fumarulo R, Corsi MM, et al. (2011) Molecular pathways in cancer-related inflammation. Biochem Med (Zagreb) 21: 264-275.
18. Mantovani A, Allavena P, Sica A, Balkwill F, (2008) Cancer-related inflammation. Nature 454: 436-444.
19. Ramos EA, Grochoski M, Braun-Prado K, Seniski GG, Cavalli IJ, et al. (2011) Epigenetic changes of CXCR4 and its ligand CXCL12 as prognostic factors for sporadic breast cancer. PLoS One 6: e29461.
20. Gialeli C, Theocharis AD, Karamanos NK, (2011) Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J 278: 16-27.
21. Statistics USC (2008) 1999-2008 Cancer Incidence and Mortality Data. Atlanta, GA.
22. Schreiber S, Rosenstiel P, Hampe J, Nikolaus S, Groessner B, et al. (2002) Activation of signal transducer and activator of transcription (STAT) 1 in human chronic inflammatory bowel disease. Gut 51: 379-385.
23. Cheung KL, Khor TO, Huang MT, Kong AN, (2010) Differential in vivo mechanism of chemoprevention of tumor formation in azoxymethane/dextran sodium sulfate mice by PEITC and DBM. Carcinogenesis 31: 880-885.
24. Suzuki M, Hisamatsu T, Podolsky DK, (2003) Gamma interferon augments the intracellular pathway for lipopolysaccharide (LPS) recognition in human intestinal epithelial cells through coordinated up-regulation of LPS uptake and expression of the intracellular Toll-like receptor 4-MD-2 complex. Infect Immun 71: 3503-3511.
25. Livak KJ, Schmittgen TD, (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
26. Angrisano T, Pero R, Peluso S, Keller S, Sacchetti S, et al. (2010) LPS-induced IL-8 activation in human intestinal epithelial cells is accompanied by specific histone H3 acetylation and methylation changes. BMC Microbiol 10: 172.
27. Wagschal A, Delaval K, Pannetier M, Arnaud P, Feil R (2007) Chromatin Immunoprecipitation (ChIP) on Unfixed Chromatin from Cells and Tissues to Analyze Histone Modifications. CSH Protoc 2007: pdb prot4767.
28. Haring M, Offermann S, Danker T, Horst I, Peterhansel C, et al. (2007) Chromatin immunoprecipitation: optimization, quantitative analysis and data normalization. Plant Methods 3: 11.
29. Maharshak N, Hart G, Ron E, Zelman E, Sagiv A, et al. (2010) CCL2 (pM levels) as a therapeutic agent in Inflammatory Bowel Disease models in mice. Inflamm Bowel Dis 16: 1496-1504.
30. De Santa F, Totaro MG, Prosperini E, Notarbartolo S, Testa G, et al. (2007) The histone H3 lysine-27 demethylase Jmjd3 links inflammation to inhibition of polycomb-mediated gene silencing. Cell 130: 1083-1094.
31. Hahn MA, Hahn T, Lee DH, Esworthy RS, Kim BW, et al. (2008) Methylation of polycomb target genes in intestinal cancer is mediated by inflammation. Cancer Res 68: 10280-10289.
32. Tahk S, Liu B, Chernishof V, Wong KA, Wu H, et al. (2007) Control of specificity and magnitude of NF-kappa B and STAT1-mediated gene activation through PIASy and PIAS1 cooperation. Proc Natl Acad Sci U S A 104: 11643-11648.
33. Fiorucci S, Orlandi S, Mencarelli A, Caliendo G, Santagada V, et al. (2007) Enhanced activity of a hydrogen sulphide-releasing derivative of mesalamine (ATB-429) in a mouse model of colitis. Br J Pharmacol 150: 996-1002.
34. Chen YH, Dai HJ, Chang HP, (2003) Suppression of inducible nitric oxide production by indole and isothiocyanate derivatives from Brassica plants in stimulated macrophages. Planta Med 69: 696-700.
35. Gerhauser C, Klimo K, Heiss E, Neumann I, Gamal-Eldeen A, et al. (2003) Mechanism-based in vitro screening of potential cancer chemopreventive agents. Mutat Res 523-524: 163-172.
36. Rose P, Won YK, Ong CN, Whiteman M, (2005) Beta-phenylethyl and 8-methylsulphinyloctyl isothiocyanates, constituents of watercress, suppress LPS induced production of nitric oxide and prostaglandin E2 in RAW 264.7 macrophages. Nitric Oxide 12: 237-243.
37. Jeong WS, Kim IW, Hu R, Kong AN, (2004) Modulatory properties of various natural chemopreventive agents on the activation of NF-kappaB signaling pathway. Pharm Res 21: 661-670.
38. McBride KM, Reich NC, (2003) The ins and outs of STAT1 nuclear transport. Sci STKE 2003: RE13.
39. Rath T, Roderfeld M, Halwe JM, Tschuschner A, Roeb E, et al. (2010) Cellular sources of MMP-7, MMP-13 and MMP-28 in ulcerative colitis. Scand J Gastroenterol 45: 1186-1196.
40. Koskensalo S, Louhimo J, Nordling S, Hagstrom J, Haglund C, (2011) MMP-7 as a prognostic marker in colorectal cancer. Tumour Biol 32: 259-264.
41. Illemann M, Bird N, Majeed A, Sehested M, Laerum OD, et al. (2006) MMP-9 is differentially expressed in primary human colorectal adenocarcinomas and their metastases. Mol Cancer Res 4: 293-302.
42. Ho E, Dashwood RH, (2010) Dietary manipulation of histone structure and function. World Rev Nutr Diet 101: 95-102.
43. Sigalotti L, Fratta E, Coral S, Cortini E, Covre A, et al. (2007) Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications. J Cell Physiol 212: 330-344.
44. Nakamura Y, (2009) Chemoprevention by isothiocyanates: molecular basis of apoptosis induction. Forum Nutr 61: 170-181.
45. Rahman MA, Kim NH, Kim SH, Oh SM, Huh SO, (2012) Antiproliferative and cytotoxic effects of resveratrol in mitochondria-mediated apoptosis in rat b103 neuroblastoma cells. Korean J Physiol Pharmacol 16: 321-326.
46. Roh TY, Cuddapah S, Cui K, Zhao K, (2006) The genomic landscape of histone modifications in human T cells. Proc Natl Acad Sci U S A 103: 15782-15787.
47. Ficz G, Heintzmann R, Arndt-Jovin DJ, (2005) Polycomb group protein complexes exchange rapidly in living Drosophila. Development 132: 3963-3976.
48. Bannister AJ, Zegerman P, Partridge JF, Miska EA, Thomas JO, et al. (2001) Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain. Nature 410: 120-124.
49. Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, et al. (2007) High-resolution profiling of histone methylations in the human genome. Cell 129: 823-837.
50. Boyer LA, Plath K, Zeitlinger J, Brambrink T, Medeiros LA, et al. (2006) Polycomb complexes repress developmental regulators in murine embryonic stem cells. Nature 441: 349-353.
51. Han M, Grunstein M, (1988) Nucleosome loss activates yeast downstream promoters in vivo. Cell 55: 1137-1145.
52. Durrin LK, Mann RK, Kayne PS, Grunstein M, (1991) Yeast histone H4 N-terminal sequence is required for promoter activation in vivo. Cell 65: 1023-1031.
53. Wang LG, Liu XM, Fang Y, Dai W, Chiao FB, et al. (2008) De-repression of the p21 promoter in prostate cancer cells by an isothiocyanate via inhibition of HDACs and c-Myc. Int J Oncol 33: 375-380.
54. Singh SV, Kim SH, Sehrawat A, Arlotti JA, Hahm ER, et al. (2012) Biomarkers of Phenethyl Isothiocyanate-Mediated Mammary Cancer Chemoprevention in a Clinically Relevant Mouse Model. J Natl Cancer Inst.
55. Seong KH, Li D, Shimizu H, Nakamura R, Ishii S, (2011) Inheritance of stress-induced, ATF-2-dependent epigenetic change. Cell 145: 1049-1061.
56. Rando TA, Chang HY, (2012) Aging, rejuvenation, and epigenetic reprogramming: resetting the aging clock. Cell 148: 46-57.
57. Maze I, Covington HE, 3rd, Dietz DM, LaPlant Q, Renthal W, et al (2010) Essential role of the histone methyltransferase G9a in cocaine-induced plasticity. Science 327: 213-216.
58. Hewings DS, Wang M, Philpott M, Fedorov O, Uttarkar S, et al. (2011) 3,5-dimethylisoxazoles act as acetyl-lysine-mimetic bromodomain ligands. J Med Chem 54: 6761-6770.
59. Nicodeme E, Jeffrey KL, Schaefer U, Beinke S, Dewell S, et al. (2010) Suppression of inflammation by a synthetic histone mimic. Nature 468: 1119-1123.
60. Reynoird N, Schwartz BE, Delvecchio M, Sadoul K, Meyers D, et al. (2010) Oncogenesis by sequestration of CBP/p300 in transcriptionally inactive hyperacetylated chromatin domains. EMBO J 29: 2943-2952.